profit from every €100 of sales.
€0€100
ABIVAX Société Anonyme
€77.70+0.71% today
-20.4% since Dec 18, 25
1-year low €63.101-year high €135.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What ABIVAX Société Anonyme sold, what it kept, and what it did with the cash.
Sales went from €0 in 2022 to €0 in 2025, with -€336 million of profit last year.
SalesProfit
ABIVAX Société Anonyme vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| ABIVAX Société Anonyme | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads ABIVAX Société Anonyme's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| -51 | – | – | – | |
| -51 | -127 | -173 | -246 | |
| -53 | -133 | -163 | -301 | |
| -61 | -148 | -176 | -336 | |
| -3.18 | -3.43 | -2.78 | -4.83 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 76 | 327 | 205 | 584 |
| Cash | 27 | 252 | 144 | 517 |
| Total debt | 39 | 58 | 97 | 2 |
| Total liabilities | 68 | 131 | 165 | 129 |
| 7 | 196 | 41 | 455 | |
| 19 | 43 | 63 | 70 | |
| -87.1% | -39.5% | -89.1% | -49.5% | |
| -844.9% | -75.4% | -434.3% | -73.8% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -54 | -97 | -154 | -161 | |
| 0 | 0 | 1 | 0 | |
| -54 | -97 | -155 | -161 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| – | – | – | – | |
| -1 | 8 | 20 | 35 |
Valuation
- –
- –
- –
- 14.9×
- –
- –
- –
- -2.4%
- -4.9%
- –
Profitability
- –
- –
- –
- –
- -49.5%
- -66.3%
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- +53.9%
Financial health
- 1.7×
- 0.00
- –
- -10.6×
- 8.75
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 8%of 948
Bottom 29%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
18No pass
Benjamin Graham
40No pass
Philip Fisher
27No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
30No pass
Terry Smith
23No pass
Questions about ABIVAX Société Anonyme
Is ABIVAX Société Anonyme a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the ABIVAX Société Anonyme AI analysis
What does ABIVAX Société Anonyme do?
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. It is in Biotechnology, based in Paris, France, with 80 employees.
Is ABIVAX Société Anonyme stock halal?
Yes. ABIVAX Société Anonyme passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
Who are ABIVAX Société Anonyme's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with ABIVAX Société Anonyme's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.